Nephrology has had more therapeutic advances in the past five years than in the previous two decades combined — a statement that would have seemed implausible before the SGLT2 inhibitor data arrived. Dapagliflozin and empagliflozin turned out to work independently of diabetes status, which immediately expanded the eligible CKD population by millions. Finerenone added a distinct mechanism. IgA nephropathy — the most common primary glomerulonephritis globally and a leading cause of kidney failure in young adults — went from having essentially no targeted treatment to having three approved or accelerated-approval agents in 2023–2024 alone. The 2026 pipeline is building on all of this, and the wearable artificial kidney — which would have seemed like science fiction a decade ago — is in Phase 1/2 trials.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
CKD affects approximately 850 million people worldwide. Key 2026 developments: SGLT2 inhibitors (dapagliflozin, empagliflozin) are now approved for non-diabetic CKD based on DAPA-CKD and EMPA-KIDNEY, with combination trials with finerenone actively enrolling. IgA nephropathy has three new targeted agents (sparsentan, budesonide/Tarpeyo, iptacopan) with Phase 3 confirmatory trials recruiting alongside sibeprenlimab (anti-APRIL), atacicept (anti-APRIL/BAFF), and zigakibart (anti-C3). Wearable artificial kidney devices are in Phase 1/2 for continuous ambulatory dialysis. eGFR trajectory, UACR, and cause of CKD are the key variables determining trial eligibility.
ClinicalMetric Analysis
- IgA nephropathy's three new approvals require sequencing decisions that no established algorithm covers yet. Budesonide/Tarpeyo (targeted-release) works best early — eGFR above 45, active proteinuria. Sparsentan adds dual endothelin/angiotensin blockade for progressive disease not controlled on RAAS therapy. Iptacopan inhibits complement factor B for the C3-heavy phenotype. These have overlapping and distinct eligibility criteria, and no head-to-head data exists. Treatment sequencing across these agents is currently physician judgment, not evidence-based protocol.
- Complement-mediated glomerulonephritis (C3G, IC-MPGN) has targeted therapy options that most community nephrologists aren't yet testing for. Eculizumab and avacopan trials require a complement pathway workup rarely performed outside academic centers — C3, C4, AH50, CH50, factor H autoantibodies, and often genetic complement sequencing. Patients with persistent proteinuria from glomerulonephritis who haven't had this panel should ask explicitly. The presence of a complement pathway mutation or autoantibody is the prerequisite for the trials most likely to help them.
- The wearable artificial kidney is further from clinical use than its press coverage suggests. Phase 1/2 trials are primarily addressing device safety — membrane fouling, ion balance stability over days to weeks, and miniaturization for ambulatory use. The technical challenge of maintaining continuous dialysis equivalence without tethering to a machine is substantial. Current data covers hours to days of use; the clinical target is weeks of continuous wear. Patients on dialysis should understand this as a technology in early-stage development, not an imminent option.
SGLT2 Inhibitors: The Most Practice-Changing Development in Nephrology in a Decade
The DAPA-CKD trial (dapagliflozin in CKD with or without T2DM) showed a 39% relative risk reduction in a composite of worsening kidney function, ESKD, or death from renal or cardiovascular causes compared to placebo. The EMPA-KIDNEY trial (empagliflozin in CKD) showed a 28% relative risk reduction in the primary composite of kidney disease progression or cardiovascular death. Both trials enrolled patients across the diabetic and non-diabetic CKD spectrum, and the benefits were consistent regardless of diabetes status — which immediately expanded the eligible population to tens of millions of patients globally who don't have T2DM.
The mechanisms are multiple and still not fully resolved: SGLT2 inhibition reduces intraglomerular pressure by reducing tubuloglomerular feedback-mediated afferent arteriole dilation, reducing hyperfiltration. It also reduces albuminuria, has direct anti-inflammatory effects on the proximal tubule, and affects mitochondrial metabolism in ways that appear protective against tubular injury. The 2026 trial agenda is examining SGLT2 inhibitors in kidney transplant recipients, patients on dialysis, and in fixed-dose combination with finerenone — testing whether the distinct mechanisms are additive in CKD patients with diabetes (where both are individually approved).
IgA Nephropathy: Three New Drugs and a Crowded Pipeline
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide — characterized by mesangial deposition of poorly galactosylated IgA1 that triggers complement activation and progressive inflammation. Until 2021, treatment was essentially limited to RAS blockade (ACE inhibitors, ARBs) and supportive care, with immunosuppression reserved for the highest-risk patients. That changed rapidly:
- Sparsentan (Filspari): A dual endothelin-angiotensin receptor blocker (DEARA) that addresses both hemodynamic and inflammatory components. FDA accelerated approval 2023 based on proteinuria reduction — the PROTECT Phase 3 trial showed a 49% reduction in proteinuria at 2 years versus irbesartan, with confirmatory kidney function endpoint data supporting full approval.
- Budesonide (Tarpeyo/Nefecon): A targeted-release oral budesonide formulation that releases drug specifically in the ileum, where Peyer's patches produce the poorly galactosylated IgA1. Phase 3 NefIgArd trial showed a 49% reduction in proteinuria versus placebo at 9 months, with preserved eGFR at 2 years.
- Iptacopan (Fabhalta): A complement factor B inhibitor (alternative pathway) with Phase 3 APPLAUSE-IgAN data showing 38% reduction in proteinuria. Also has an indication in PNH.
The next-generation IgAN pipeline is targeting the upstream B cell biology that drives IgA overproduction. Sibeprenlimab (anti-APRIL, Visterra/Otsuka) showed a dose-dependent 58% reduction in proteinuria in Phase 2 — APRIL drives IgA class switching and production in gut-associated lymphoid tissue. Atacicept (anti-APRIL/BAFF fusion protein) showed similar proteinuria reductions in ORIGIN Phase 2. Zigakibart (anti-C3, Alexion) targets complement at a central node. The number of active IgAN Phase 3 trials in 2026 is unprecedented — patients with progressive IgAN have more trial options now than at any previous point in the disease's history.
Rare Kidney Disease: Complement Inhibitors Transform Treatment
Complement-mediated kidney diseases have seen remarkable therapeutic progress. Avacopan (Tavneos) — a C5a receptor antagonist — is FDA-approved for ANCA-associated vasculitis (ANCA-AAV) as an alternative to high-dose glucocorticoids, reducing steroid toxicity while maintaining remission rates. Iptacopan and pegcetacoplan are in Phase 2 and 3 trials for C3 glomerulopathy (C3G) and membranoproliferative glomerulonephritis (MPGN), diseases where complement dysregulation is the primary mechanism and treatment options have historically been extremely limited. For atypical HUS (complement-mediated thrombotic microangiopathy), eculizumab and ravulizumab (both anti-C5 monoclonal antibodies) are established treatments, with danicopan (oral factor D inhibitor) in trials for the subset of patients with residual breakthrough activity on C5 blockade.
For patients with rare genetic kidney diseases — Alport syndrome, FSGS with specific mutations, PKD — whole exome sequencing increasingly identifies actionable variants and matches patients to relevant trials. The era of treating these diseases as monolithic entities is ending; the trial landscape now reflects the genetic heterogeneity underlying what we used to call a single diagnosis.
Dialysis Innovation: Wearable Artificial Kidney
Conventional hemodialysis requires patients to be tethered to a machine for 3–4 hours, three times per week — a profound lifestyle constraint with cardiovascular consequences from the intermittent rather than continuous removal of fluid and solutes. Peritoneal dialysis offers more flexibility but has infection risks and technique limitations. The wearable artificial kidney (WAK) is a conceptually simple but technically demanding device: a miniaturized dialysis system worn on the body that provides slow, continuous clearance while the patient moves freely. Phase 1/2 trials are demonstrating safety and efficacy in controlled settings; regulatory approval depends on confirming both technical reliability over extended wear periods and patient-centered outcomes including quality of life and cardiovascular stability.
Bioartificial kidney devices — combining a conventional hemofilter with living proximal tubule cells that perform the metabolic and endocrine functions that hemodialysis doesn't replicate — are in late preclinical development. This would address not just clearance but also erythropoietin production, vitamin D activation, and other kidney functions that currently require pharmaceutical supplementation in dialysis patients.
Key Data Points
- DAPA-CKD: dapagliflozin reduced the composite of worsening kidney function, ESKD, or death by 39% in non-diabetic and diabetic CKD — establishing SGLT2 inhibitors as a disease class independent of diabetes.
- Sparsentan PROTECT Phase 3: 49% proteinuria reduction versus irbesartan at 2 years in IgA nephropathy — the first targeted therapy approval for IgAN was a watershed moment for the field.
- Sibeprenlimab (anti-APRIL): up to 58% proteinuria reduction in Phase 2 IgAN — targeting the B cell biology driving aberrant IgA production rather than the downstream consequences.
- Avacopan (Tavneos): approved for ANCA-AAV as steroid-sparing alternative — established complement inhibition as a therapeutic strategy in inflammatory kidney disease.
- eGFR trajectory, urine albumin-to-creatinine ratio (UACR), and cause of CKD (diabetic, IgAN, FSGS, ANCA-AAV, hypertensive) determine trial eligibility — have recent labs and kidney biopsy report ready before contacting any study site.
How to Access Kidney Disease Trials
Nephrology departments at academic medical centers run the highest concentration of CKD, IgAN, and rare kidney disease trials. Search ClinicalMetric for "chronic kidney disease," "IgA nephropathy," or "FSGS" filtered to Phase 2/3, Recruiting, within your region. The three data points that matter most for pre-screening conversations: most recent eGFR, most recent UACR, and kidney biopsy pathology report if available. Most investigators want these before discussing eligibility — don't contact a trial site without them if at all possible.